(Q40000644)

16 September 2017

Assessing vaccine potency using TCRmimic antibodies (English)

1 reference

16 September 2017

Francisca A Neethling

1

1 reference

16 September 2017

Venky Ramakrishna

2

1 reference

16 September 2017

Tibor Keler

3

1 reference

16 September 2017

Rico Buchli

4

1 reference

16 September 2017

Tito Woodburn

5

1 reference

16 September 2017

Jon A Weidanz

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

25 February 2008

1 reference

16 September 2017

1 reference

16 September 2017

26

1 reference

16 September 2017

25

1 reference

16 September 2017

3092-3102

1 reference

Personalized peptide vaccines: a new therapeutic modality for cancer

16 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

A listing of human tumor antigens recognized by T cells: March 2004 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Immune monitoring of T-cell responses in cancer vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Immune monitoring of human gene therapy trials: potential application to leukemia and lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Direct detection of cellular immune responses to cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Phenotypic analysis of antigen-specific T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Overexpression of native human beta 2-microglobulin in Escherichia coli and its purification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.025

10.1016/J.VACCINE.2008.02.025

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference